Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Intestinal Obstruction II: Pathophysiology01:07

Intestinal Obstruction II: Pathophysiology

Intestinal obstruction triggers a series of physiological responses, starting with gas and fluid accumulation in the bowel segment proximal to the obstruction, leading to distension. This distended intestine compresses the diaphragm, hindering lung expansion and potentially leading to reduced respiratory effort, atelectasis, and pneumonia.To overcome the blockage, the gut intensifies contractions, causing colicky abdominal pain, nausea, and vomiting, which reduces fluid and food intake and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease.

Basic & clinical pharmacology & toxicology·2026
Same author

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial.

EULAR rheumatology open·2026
Same author

Amylase and lipase in alcohol-induced acute pancreatitis: Time to rethink diagnostic thresholds?

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026
Same author

European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations.

United European gastroenterology journal·2026
Same author

Fulminant Hepatic Failure Following Initiation of Abiraterone in Metastatic Prostate Cancer: A Fatal Adverse Drug Reaction.

Case reports in hepatology·2026
Same author

Digitally supported, patient-initiated care: Maintaining control of inflammatory bowel diseases while achieving high patient satisfaction.

International journal of medical informatics·2026

Related Experiment Video

Updated: May 18, 2026

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
09:44

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

Opioid-induced bowel dysfunction: pathophysiology and management.

Christina Brock1, Søren Schou Olesen, Anne Estrup Olesen

  • 1Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. cb@mech-sense.com

Drugs
|September 7, 2012
PubMed
Summary

Opioid medications cause significant side effects, including opioid-induced bowel dysfunction (OIBD), which impacts patient quality of life. New treatments show promise but require further clinical trials to confirm superiority over traditional laxatives.

More Related Videos

Postoperative Ileus Murine Model
04:26

Postoperative Ileus Murine Model

Published on: July 12, 2024

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

Related Experiment Videos

Last Updated: May 18, 2026

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
09:44

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

Postoperative Ileus Murine Model
04:26

Postoperative Ileus Murine Model

Published on: July 12, 2024

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

Area of Science:

  • Gastroenterology
  • Pain Management
  • Pharmacology

Background:

  • Opioids are widely prescribed for severe pain, with up to 90% of patients in US pain centers receiving them.
  • Opioid use is associated with numerous side effects, including nausea, cognitive impairment, addiction, and urinary retention.
  • Opioid-induced bowel dysfunction (OIBD) arises from opioid action on the enteric nervous system, leading to gut dysmotility and related symptoms like constipation.

Purpose of the Study:

  • To review the challenges and current treatment strategies for opioid-induced bowel dysfunction (OIBD).
  • To explore the pathophysiology of OIBD and its clinical manifestations.
  • To evaluate the efficacy of existing and emerging treatments for OIBD.

Main Methods:

  • Review of current literature on opioid use, side effects, and OIBD.
  • Discussion of diagnostic methods for OIBD, including subjective scales and objective assessments like radiography and manometry.
  • Analysis of various treatment approaches, from traditional laxatives to newer prokinetics and opioid antagonists.

Main Results:

  • OIBD is a common and severe side effect of opioid therapy, significantly impacting treatment adherence and patient well-being.
  • Traditional laxatives are often insufficient for managing OIBD symptoms, particularly those affecting the upper gastrointestinal tract.
  • Emerging treatments like prokinetics (e.g., prucalopride, lubiprostone) and peripherally acting opioid antagonists show potential but require further clinical validation.

Conclusions:

  • Opioid-induced bowel dysfunction (OIBD) remains a significant clinical challenge, often limiting effective pain management.
  • While newer pharmacological agents demonstrate promise, their superiority over standard laxative regimens needs robust clinical trial evidence.
  • Further research is essential to develop and validate more effective strategies for managing OIBD and improving patient outcomes in pain management.